The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the 'Rete Ematologica Lombarda'

MLA

Molteni, A., et al. The Influence of Disease and Comorbidity Risk Assessments on the Survival of MDS and Oligoblastic AML Patients Treated with 5-Azacitidine: A Retrospective Analysis in Ten Centers of the “Rete Ematologica Lombarda.” 2016. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1376787958&authtype=sso&custid=ns315887.

APA

Molteni, A., Riva, M., Borin, L., Bernardi, M., Pelizzari, A., Freyrie, A., Della Porta, M., Nichelatti, M., Ravano, E., Quaresmini, G., Mariotti, J., Caramazza, D., Ubezio, M., Guarco, S., Gigli, F., Greco, R., Cairoli, R., Morra, E., Molteni A, … Morra E. (2016). The influence of disease and comorbidity risk assessments on the survival of MDS and oligoblastic AML patients treated with 5-azacitidine: A retrospective analysis in ten centers of the “Rete Ematologica Lombarda.”

Chicago

Molteni, A, M Riva, L Borin, M Bernardi, A Pelizzari, A Freyrie, M Della Porta, et al. 2016. “The Influence of Disease and Comorbidity Risk Assessments on the Survival of MDS and Oligoblastic AML Patients Treated with 5-Azacitidine: A Retrospective Analysis in Ten Centers of the ‘Rete Ematologica Lombarda.’” http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsoai&AN=edsoai.on1376787958&authtype=sso&custid=ns315887.